LIVN LivaNova PLC
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1639691 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.7%
TTM net income YoY190.1%
TTM EPS YoY187.7%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR308.9%
Margins
Gross margin67.8%
Operating margin10.7%
Net margin13.0%
FCF margin8.6%
EBITDA margin13.0%
Returns
ROE15.5%
ROA7.4%
ROIC (approx.)15.8%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.22x
Current ratio1.46x
Interest coverage4.73x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue7.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $393.15M | $390.59M | $362.26M | $360.92M | $357.75M | $352.52M | $316.86M | $321.83M |
| Cost of revenue | $128.10M | $116.92M | $118.51M | $121.15M | $112.90M | $113.54M | $100.60M | $107.46M |
| Gross profit | $265.05M | $273.67M | $243.75M | $239.77M | $244.85M | $238.99M | $216.25M | $214.37M |
| R&D expense | $47.69M | $53.66M | $58.70M | $52.12M | $48.58M | $47.19M | $37.88M | $43.31M |
| SG&A expense | $154.93M | $158.13M | $143.57M | $143.37M | $138.52M | $137.78M | $129.15M | $130.64M |
| Operating income | $28.43M | $49.48M | $41.47M | $42.58M | $54.01M | $54.18M | $48.62M | $37.02M |
| Interest expense | $7.95M | $7.18M | $8.29M | $10.86M | $10.86M | $14.93M | $15.29M | $15.77M |
| Pretax income | $46.77M | $18.48M | $27.48M | $27.63M | $33.91M | $33.32M | -$315.65M | $56.48M |
| Income tax | $12.40M | -$90.20M | $4.34M | -$3.28M | $7.11M | $6.15M | $11.66M | $589,000 |
| Net income | $34.29M | $108.57M | $22.29M | $30.91M | $26.78M | $27.16M | -$327.32M | $55.89M |
| EBITDA | $37.53M | $58.24M | $49.77M | $50.13M | $61.73M | $61.06M | $55.04M | $43.44M |
| EPS (basic) | 0.62 | 1.98 | 0.41 | — | 0.49 | 0.50 | -6.01 | — |
| EPS (diluted) | 0.11 | 1.93 | 0.40 | — | 0.49 | 0.50 | -6.01 | — |
| Weighted avg. shares (diluted) | 57.37M | 56.27M | 55.94M | — | 55.15M | 54.71M | 54.42M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $563.47M | $516.62M | $539.71M | $635.55M | $646.08M | $593.64M | $738.44M | $723.56M |
| Receivables | $236.37M | $231.30M | $229.27M | $215.99M | $211.58M | $220.19M | $202.08M | $193.16M |
| Inventory | $177.88M | $172.61M | $165.50M | $164.70M | $167.54M | $165.35M | $154.02M | $147.57M |
| Current assets | $1.08B | $1.03B | $1.01B | $1.10B | $1.10B | $1.07B | $1.17B | $1.13B |
| PP&E, net | $293.32M | $273.33M | $255.48M | $242.60M | $218.51M | $195.42M | $177.68M | $170.26M |
| Goodwill | $778.80M | $779.14M | $785.59M | $792.84M | $791.03M | $793.37M | $761.91M | $750.01M |
| Intangibles | $210.73M | $217.00M | $224.56M | $229.96M | $234.53M | $239.14M | $236.59M | $237.29M |
| Total assets | $2.71B | $2.64B | $2.52B | $2.61B | $2.56B | $2.51B | $2.56B | $2.51B |
| Current liabilities | $740.19M | $707.00M | $762.48M | $808.07M | $827.59M | $827.10M | $741.57M | $392.12M |
| Short-term debt | $3.90M | $3.58M | $2.63M | $31.47M | $85.44M | $82.13M | $79.57M | $78.00M |
| Long-term debt | $295.19M | $289.91M | $285.16M | $345.19M | $349.03M | $348.49M | $549.22M | $549.62M |
| Total debt | $299.09M | $293.49M | $287.79M | $376.66M | $434.47M | $430.62M | $628.79M | $627.63M |
| Total liabilities | $1.34B | $1.32B | $1.31B | $1.41B | $1.40B | $1.38B | $1.52B | $1.19B |
| Shareholders' equity | $1.37B | $1.33B | $1.21B | $1.20B | $1.16B | $1.12B | $1.03B | $1.32B |
| Net debt | -$264.38M | -$223.13M | -$251.92M | -$258.89M | -$211.61M | -$163.02M | -$109.64M | -$95.93M |
| Shares outstanding | 55.09M | 55.05M | 54.90M | 54.65M | 54.61M | 54.59M | 54.52M | 54.35M |
| Cash flow statement | ||||||||
| Operating cash flow | $73.66M | $66.59M | $15.22M | $82.40M | $85.06M | $62.92M | $23.97M | $78.71M |
| Capital expenditure | $30.77M | $31.55M | $14.29M | $32.23M | $22.88M | $15.15M | $10.79M | $10.41M |
| Free cash flow | $42.89M | $35.04M | $926,000 | $50.16M | $62.18M | $47.77M | $13.18M | $68.30M |
| Investing cash flow | -$23.11M | -$31.92M | -$14.58M | -$30.26M | -$23.06M | -$8.97M | -$10.63M | -$10.71M |
| Financing cash flow | -$2.92M | -$56.45M | -$94.25M | -$62.88M | -$9.37M | -$208.98M | -$4.42M | -$3.44M |
| Depreciation & amortization | $9.10M | $8.75M | $8.30M | $7.55M | $7.71M | $6.87M | $6.42M | $6.42M |
| Stock-based compensation | $14.55M | $16.88M | $8.27M | $9.39M | $9.95M | $9.17M | $7.78M | $6.95M |
Free plan shows the latest 8 periods; Pro shows all 56 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.